Listed

Kymera Therapeutics, Inc.

KYMRNasdaqCIK 1815442HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$65.0m, Q2 FY2026
Operating income−$75.6m, Q2 FY2026
Net income−$61.2m, Q2 FY2026
Kymera Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m4.7Revenue, Q3 FY2023, three months to 2023-09-30$4.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-10-31, accession 0000950170-24-119249.Report this figure47.9Revenue, Q4 FY2023, three months to 2023-12-31$47.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure10.3Revenue, Q1 FY2024, three months to 2024-03-31$10.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-09, accession 0000950170-25-067498.Report this figure25.7Revenue, Q2 FY2024, three months to 2024-06-30$25.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-11, accession 0000950170-25-106229.Report this figure3.7Revenue, Q3 FY2024, three months to 2024-09-30$3.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure7.4Revenue, Q4 FY2024, three months to 2024-12-31$7.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure22.1Revenue, Q1 FY2025, three months to 2025-03-31$22.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure11.5Revenue, Q2 FY2025, three months to 2025-06-30$11.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure2.8Revenue, Q3 FY2025, three months to 2025-09-30$2.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure2.9Revenue, Q4 FY2025, three months to 2025-12-31$2.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure34.4Revenue, Q1 FY2026, three months to 2026-03-31$34.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure65.0Revenue, Q2 FY2026, three months to 2026-06-30$65.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure
Cost of revenue$mnot reportednot reported10.3Cost of revenue, Q1 FY2024, three months to 2024-03-31$10.3m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-05-09, accession 0000950170-25-067498.Report this figure25.7Cost of revenue, Q2 FY2024, three months to 2024-06-30$25.6m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-08-11, accession 0000950170-25-106229.Report this figure3.7Cost of revenue, Q3 FY2024, three months to 2024-09-30$3.7m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure7.4Cost of revenue, Q4 FY2024, three months to 2024-12-31$7.4m. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure22.1Cost of revenue, Q1 FY2025, three months to 2025-03-31$22.1m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure11.5Cost of revenue, Q2 FY2025, three months to 2025-06-30$11.5m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure2.8Cost of revenue, Q3 FY2025, three months to 2025-09-30$2.8m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure2.9Cost of revenue, Q4 FY2025, three months to 2025-12-31$2.9m. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure34.4Cost of revenue, Q1 FY2026, three months to 2026-03-31$34.4m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure65.0Cost of revenue, Q2 FY2026, three months to 2026-06-30$65.0m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure
Research and development$m48.1Research and development, Q3 FY2023, three months to 2023-09-30$48.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-10-31, accession 0000950170-24-119249.Report this figure53.0Research and development, Q4 FY2023, three months to 2023-12-31$53.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure48.8Research and development, Q1 FY2024, three months to 2024-03-31$48.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-09, accession 0000950170-25-067498.Report this figure59.2Research and development, Q2 FY2024, three months to 2024-06-30$59.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-11, accession 0000950170-25-106229.Report this figure60.4Research and development, Q3 FY2024, three months to 2024-09-30$60.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure71.8Research and development, Q4 FY2024, three months to 2024-12-31$71.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure80.3Research and development, Q1 FY2025, three months to 2025-03-31$80.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure78.4Research and development, Q2 FY2025, three months to 2025-06-30$78.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure74.1Research and development, Q3 FY2025, three months to 2025-09-30$74.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure83.8Research and development, Q4 FY2025, three months to 2025-12-31$83.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure98.2Research and development, Q1 FY2026, three months to 2026-03-31$98.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure119Research and development, Q2 FY2026, three months to 2026-06-30$119.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure
Operating income$m(57.5)Operating income, Q3 FY2023, three months to 2023-09-30−$57.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-10-31, accession 0000950170-24-119249.Report this figure(19.3)Operating income, Q4 FY2023, three months to 2023-12-31−$19.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure(57.8)Operating income, Q1 FY2024, three months to 2024-03-31−$57.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-09, accession 0000950170-25-067498.Report this figure(50.9)Operating income, Q2 FY2024, three months to 2024-06-30−$50.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-11, accession 0000950170-25-106229.Report this figure(72.1)Operating income, Q3 FY2024, three months to 2024-09-30−$72.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure(80.8)Operating income, Q4 FY2024, three months to 2024-12-31−$80.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure(74.4)Operating income, Q1 FY2025, three months to 2025-03-31−$74.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure(84.6)Operating income, Q2 FY2025, three months to 2025-06-30−$84.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure(92.5)Operating income, Q3 FY2025, three months to 2025-09-30−$92.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure(97.9)Operating income, Q4 FY2025, three months to 2025-12-31−$97.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure(84.2)Operating income, Q1 FY2026, three months to 2026-03-31−$84.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure(75.6)Operating income, Q2 FY2026, three months to 2026-06-30−$75.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure
Income tax$m0.1Income tax, Q3 FY2023, three months to 2023-09-30$100.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2023-11-02, accession 0000950170-23-057743.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(52.9)Net income, Q3 FY2023, three months to 2023-09-30−$52.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-10-31, accession 0000950170-24-119249.Report this figure(14.4)Net income, Q4 FY2023, three months to 2023-12-31−$14.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure(48.6)Net income, Q1 FY2024, three months to 2024-03-31−$48.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-09, accession 0000950170-25-067498.Report this figure(42.1)Net income, Q2 FY2024, three months to 2024-06-30−$42.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-11, accession 0000950170-25-106229.Report this figure(62.5)Net income, Q3 FY2024, three months to 2024-09-30−$62.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure(70.8)Net income, Q4 FY2024, three months to 2024-12-31−$70.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure(65.6)Net income, Q1 FY2025, three months to 2025-03-31−$65.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure(76.6)Net income, Q2 FY2025, three months to 2025-06-30−$76.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure(82.2)Net income, Q3 FY2025, three months to 2025-09-30−$82.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure(87.0)Net income, Q4 FY2025, three months to 2025-12-31−$87.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure(69.2)Net income, Q1 FY2026, three months to 2026-03-31−$69.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure(61.2)Net income, Q2 FY2026, three months to 2026-06-30−$61.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure
Diluted EPS$ per share(0.90)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.90 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-10-31, accession 0000950170-24-119249.Report this figurenot reported(0.69)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.69 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-09, accession 0000950170-25-067498.Report this figure(0.58)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.58 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-11, accession 0000950170-25-106229.Report this figure(0.82)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.82 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figurenot reported(0.82)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.82 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure(0.95)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.95 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure(0.94)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.94 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figurenot reported(0.71)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.71 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure(0.62)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure
Basic EPS$ per share(0.90)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.90 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-10-31, accession 0000950170-24-119249.Report this figurenot reported(0.69)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.69 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-09, accession 0000950170-25-067498.Report this figure(0.58)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.58 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-11, accession 0000950170-25-106229.Report this figure(0.82)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.82 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figurenot reported(0.82)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.82 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure(0.95)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.95 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure(0.94)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.94 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figurenot reported(0.71)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.71 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure(0.62)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.62 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure

Balance sheet

Cash and equivalents$124.5m, Q2 FY2026
Shareholders' equity$1.51bn, Q2 FY2026
Kymera Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m81.1Cash and equivalents, Q3 FY2023, at 2023-09-30$81.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-10-31, accession 0000950170-24-119249.Report this figure110Cash and equivalents, FY2023, at 2023-12-31$110.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-26, accession 0001193125-26-073395.Report this figure93.5Cash and equivalents, Q1 FY2024, at 2024-03-31$93.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-09, accession 0000950170-25-067498.Report this figure67.6Cash and equivalents, Q2 FY2024, at 2024-06-30$67.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-11, accession 0000950170-25-106229.Report this figure111Cash and equivalents, Q3 FY2024, at 2024-09-30$110.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure120Cash and equivalents, FY2024, at 2024-12-31$120.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-26, accession 0001193125-26-073395.Report this figure90.0Cash and equivalents, Q1 FY2025, at 2025-03-31$90.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure336Cash and equivalents, Q2 FY2025, at 2025-06-30$335.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure113Cash and equivalents, Q3 FY2025, at 2025-09-30$112.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure357Cash and equivalents, FY2025, at 2025-12-31$357.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure144Cash and equivalents, Q1 FY2026, at 2026-03-31$144.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure124Cash and equivalents, Q2 FY2026, at 2026-06-30$124.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure
Current assets$m376Current assets, Q3 FY2023, at 2023-09-30$375.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-02, accession 0000950170-23-057743.Report this figure405Current assets, FY2023, at 2023-12-31$405.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-27, accession 0000950170-25-028355.Report this figure537Current assets, Q1 FY2024, at 2024-03-31$537.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-02, accession 0000950170-24-051567.Report this figure525Current assets, Q2 FY2024, at 2024-06-30$525.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-07, accession 0000950170-24-092275.Report this figure569Current assets, Q3 FY2024, at 2024-09-30$568.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-10-31, accession 0000950170-24-119249.Report this figure510Current assets, FY2024, at 2024-12-31$510.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-26, accession 0001193125-26-073395.Report this figure501Current assets, Q1 FY2025, at 2025-03-31$501.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-09, accession 0000950170-25-067498.Report this figure728Current assets, Q2 FY2025, at 2025-06-30$728.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-11, accession 0000950170-25-106229.Report this figure528Current assets, Q3 FY2025, at 2025-09-30$528.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure871Current assets, FY2025, at 2025-12-31$871.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure677Current assets, Q1 FY2026, at 2026-03-31$677.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure737Current assets, Q2 FY2026, at 2026-06-30$737.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure
Total assets$m552Total assets, Q3 FY2023, at 2023-09-30$552.4m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-02, accession 0000950170-23-057743.Report this figure576Total assets, FY2023, at 2023-12-31$575.8m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-27, accession 0000950170-25-028355.Report this figure868Total assets, Q1 FY2024, at 2024-03-31$868.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-02, accession 0000950170-24-051567.Report this figure826Total assets, Q2 FY2024, at 2024-06-30$826.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-07, accession 0000950170-24-092275.Report this figure1,035Total assets, Q3 FY2024, at 2024-09-30$1.03bn. XBRL concept us-gaap:Assets. 10-Q filed 2024-10-31, accession 0000950170-24-119249.Report this figure978Total assets, FY2024, at 2024-12-31$978.0m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-26, accession 0001193125-26-073395.Report this figure918Total assets, Q1 FY2025, at 2025-03-31$918.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-09, accession 0000950170-25-067498.Report this figure1,131Total assets, Q2 FY2025, at 2025-06-30$1.13bn. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-11, accession 0000950170-25-106229.Report this figure1,102Total assets, Q3 FY2025, at 2025-09-30$1.10bn. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure1,743Total assets, FY2025, at 2025-12-31$1.74bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure1,669Total assets, Q1 FY2026, at 2026-03-31$1.67bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure1,645Total assets, Q2 FY2026, at 2026-06-30$1.65bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure
Current liabilities$m63.2Current liabilities, Q3 FY2023, at 2023-09-30$63.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-02, accession 0000950170-23-057743.Report this figure85.7Current liabilities, FY2023, at 2023-12-31$85.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-27, accession 0000950170-25-028355.Report this figure56.1Current liabilities, Q1 FY2024, at 2024-03-31$56.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-02, accession 0000950170-24-051567.Report this figure62.1Current liabilities, Q2 FY2024, at 2024-06-30$62.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-07, accession 0000950170-24-092275.Report this figure66.5Current liabilities, Q3 FY2024, at 2024-09-30$66.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-10-31, accession 0000950170-24-119249.Report this figure67.8Current liabilities, FY2024, at 2024-12-31$67.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-26, accession 0001193125-26-073395.Report this figure59.0Current liabilities, Q1 FY2025, at 2025-03-31$59.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-09, accession 0000950170-25-067498.Report this figure87.5Current liabilities, Q2 FY2025, at 2025-06-30$87.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-11, accession 0000950170-25-106229.Report this figure71.6Current liabilities, Q3 FY2025, at 2025-09-30$71.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure83.2Current liabilities, FY2025, at 2025-12-31$83.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure62.6Current liabilities, Q1 FY2026, at 2026-03-31$62.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure71.3Current liabilities, Q2 FY2026, at 2026-06-30$71.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure
Total liabilities$m157Total liabilities, Q3 FY2023, at 2023-09-30$156.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-02, accession 0000950170-23-057743.Report this figure181Total liabilities, FY2023, at 2023-12-31$180.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-27, accession 0000950170-25-028355.Report this figure157Total liabilities, Q1 FY2024, at 2024-03-31$157.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-02, accession 0000950170-24-051567.Report this figure141Total liabilities, Q2 FY2024, at 2024-06-30$141.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-07, accession 0000950170-24-092275.Report this figure142Total liabilities, Q3 FY2024, at 2024-09-30$141.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-10-31, accession 0000950170-24-119249.Report this figure142Total liabilities, FY2024, at 2024-12-31$142.4m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-26, accession 0001193125-26-073395.Report this figure132Total liabilities, Q1 FY2025, at 2025-03-31$132.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-09, accession 0000950170-25-067498.Report this figure160Total liabilities, Q2 FY2025, at 2025-06-30$159.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-11, accession 0000950170-25-106229.Report this figure156Total liabilities, Q3 FY2025, at 2025-09-30$155.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure163Total liabilities, FY2025, at 2025-12-31$163.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure129Total liabilities, Q1 FY2026, at 2026-03-31$129.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure136Total liabilities, Q2 FY2026, at 2026-06-30$136.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure
Shareholders' equity$m396Shareholders' equity, Q3 FY2023, at 2023-09-30$395.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-10-31, accession 0000950170-24-119249.Report this figure395Shareholders' equity, FY2023, at 2023-12-31$395.0m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-26, accession 0001193125-26-073395.Report this figure711Shareholders' equity, Q1 FY2024, at 2024-03-31$711.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-11, accession 0000950170-25-106229.Report this figure685Shareholders' equity, Q2 FY2024, at 2024-06-30$684.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure893Shareholders' equity, Q3 FY2024, at 2024-09-30$892.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure836Shareholders' equity, FY2024, at 2024-12-31$835.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure786Shareholders' equity, Q1 FY2025, at 2025-03-31$786.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure971Shareholders' equity, Q2 FY2025, at 2025-06-30$971.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure946Shareholders' equity, Q3 FY2025, at 2025-09-30$946.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure1,580Shareholders' equity, FY2025, at 2025-12-31$1.58bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure1,540Shareholders' equity, Q1 FY2026, at 2026-03-31$1.54bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure1,509Shareholders' equity, Q2 FY2026, at 2026-06-30$1.51bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure

Cash flow

Operating cash flow−$54.1m, Q2 FY2026
Capital expenditure$473.0k, Q2 FY2026
Kymera Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(31.6)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$31.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-10-31, accession 0000950170-24-119249. Derived: 9-month figure less the 6-month figure.Report this figure8.0Operating cash flow, Q4 FY2023, three months to 2023-12-31$8.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure(39.6)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$39.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-09, accession 0000950170-25-067498.Report this figure(42.9)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$42.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-11, accession 0000950170-25-106229. Derived: 6-month figure less the 3-month figure.Report this figure(50.2)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$50.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001193125-25-263550. Derived: 9-month figure less the 6-month figure.Report this figure(61.8)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$61.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure(79.2)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$79.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure(59.9)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$59.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001193125-26-333849. Derived: 6-month figure less the 3-month figure.Report this figure(27.1)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$27.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001193125-25-263550. Derived: 9-month figure less the 6-month figure.Report this figure(66.7)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$66.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure(88.8)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$88.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure(54.1)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$54.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001193125-26-333849. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m8.1Capital expenditure, Q3 FY2023, three months to 2023-09-30$8.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-10-31, accession 0000950170-24-119249. Derived: 9-month figure less the 6-month figure.Report this figure11.6Capital expenditure, Q4 FY2023, three months to 2023-12-31$11.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure7.4Capital expenditure, Q1 FY2024, three months to 2024-03-31$7.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-09, accession 0000950170-25-067498.Report this figure4.7Capital expenditure, Q2 FY2024, three months to 2024-06-30$4.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-11, accession 0000950170-25-106229. Derived: 6-month figure less the 3-month figure.Report this figure(0.2)Capital expenditure, Q3 FY2024, three months to 2024-09-30−$189.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-04, accession 0001193125-25-263550. Derived: 9-month figure less the 6-month figure.Report this figure0.9Capital expenditure, Q4 FY2024, three months to 2024-12-31$936.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure0.5Capital expenditure, Q1 FY2025, three months to 2025-03-31$467.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure0.7Capital expenditure, Q2 FY2025, three months to 2025-06-30$695.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001193125-26-333849. Derived: 6-month figure less the 3-month figure.Report this figure0.2Capital expenditure, Q3 FY2025, three months to 2025-09-30$181.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-04, accession 0001193125-25-263550. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2025, three months to 2025-12-31$106.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure0.4Capital expenditure, Q1 FY2026, three months to 2026-03-31$434.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure0.5Capital expenditure, Q2 FY2026, three months to 2026-06-30$473.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001193125-26-333849. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)98.18m, Q2 FY2026
Kymera Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares54.5Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3054,535,514 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-02, accession 0000950170-23-057743.Report this figure58.2Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3158,187,038 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-02, accession 0000950170-24-051567.Report this figure58.3Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3058,326,963 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-07, accession 0000950170-24-092275.Report this figure58.4Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3058,421,859 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-10-31, accession 0000950170-24-119249.Report this figure70.8Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3170,770,320 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-09, accession 0000950170-25-067498.Report this figure73.1Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3073,059,398 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-11, accession 0000950170-25-106229.Report this figure76.1Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3076,125,975 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure80.1Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3180,146,531 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure80.4Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3080,449,405 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure87.3Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3087,300,286 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure97.5Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3197,534,269 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure98.2Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3098,177,158 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure

Shares outstanding: 83.15mShares outstanding, period not labelled, at 2026-07-3183,150,618 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure at Jul 31, 2026, from the cover of the 10-Q filed Aug 5, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.